Literature DB >> 1962453

Synthetic peptides of Venezuelan equine encephalomyelitis virus E2 glycoprotein. III. Identification of a protective peptide derived from the carboxy-terminal extramembranal one-third of the protein.

A J Johnson1, A R Hunt, J T Roehrig.   

Abstract

To complete our analysis of the E2 glycoprotein of Venezuelan equine encephalomyelitis (VEE) virus, we prepared six synthetic peptides corresponding to the extramembranal carboxy-terminal one-third of the protein. NIH-Swiss mice were immunized with the peptides, and antipeptide and antiviral titers were determined by enzyme-linked immunosorbent assay (ELISA). Challenge studies revealed that peptide 13 (amino acids 241-265) protected 60-70% of virus-challenged mice. Although the other peptides generally elicited antipeptide ELISA titers but no or low antiviral titers and did not protect mice, significant E2 reactivity was found in immunoblots. These results provide the first direct evidence that much of the E2 carboxy-terminal domain is cryptic in the VEE virion, even when virus was bound to polystyrene ELISA plates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1962453     DOI: 10.1016/0042-6822(91)90555-p

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection.

Authors:  E V Agapov; I A Razumov; I V Frolov; A A Kolykhalov; S V Netesov; V B Loktev
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Suppressors of cleavage-site mutations in the p62 envelope protein of Semliki Forest virus reveal dynamics in spike structure and function.

Authors:  I Tubulekas; P Liljeström
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

3.  Glycoproteins E2 of the Venezuelan and eastern equine encephalomyelitis viruses contain multiple cross-reactive epitopes.

Authors:  A V Pereboev; I A Razumov; V A Svyatchenko; V B Loktev
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

5.  The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.

Authors:  Ann R Hunt; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

6.  Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Authors:  Pankaj Pal; Kimberly A Dowd; James D Brien; Melissa A Edeling; Sergey Gorlatov; Syd Johnson; Iris Lee; Wataru Akahata; Gary J Nabel; Mareike K S Richter; Jolanda M Smit; Daved H Fremont; Theodore C Pierson; Mark T Heise; Michael S Diamond
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.